Key Drivers
- Strong liquidity
- Zero revenue
- Ongoing cash burn
AIAI Summary
CLYM is now materially de-risked on funding with cash into 2028 and Fast Track support, so the investment case has shifted from survival to whether the 2026 pMN/ITP/SLE readouts deliver clear patient-level efficacy—without that proof, the stock remains a high-beta, event-driven biotech rather than a durable rerating story.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Zero revenue
- •Ongoing cash burn
CLYM has an exceptionally strong, low-debt balance sheet, but zero revenue, persistent losses, negative free cash flow, and declining cash make it a high-risk story dependent on financial holdings rather than operations.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Sharp pullback
- •Overhead resistance
CLYM has stayed in an uptrend over the last month with higher lows and a strong rebound, but it remains range-bound until it clears $11.33-$12.22 while $10.50-$10.90 is the key support to hold.
Sharp drop from $12.22 on 2026-05-06 to $9.65 on 2026-05-19 shows elevated volatility
Sentiment & News
Key News Insights:
- •Funding boost
- •B-cell depletion
- •2026 catalysts
Climb Bio boosted its funding and advanced budoprutug/CLYM116 development with encouraging early data, active trial enrollment, and several 2026 clinical catalysts ahead.
The news is modestly positive for CLYM as fresh capital and advancing clinical/regulatory milestones improve visibility into upcoming readouts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings